Loading...
•
Dec 31, 2023
NeoGenomics Q4 2023 Earnings Report
NeoGenomics' Q4 2023 results showcased business momentum with long-term, sustainable growth.
Key Takeaways
NeoGenomics reported a 12% increase in fourth quarter consolidated revenue, reaching $156 million. Clinical Services revenue increased by 20% to $130 million, while Advanced Diagnostics revenue decreased by 17% to $25 million. The company's net loss decreased by 37% to $14 million, and Adjusted EBITDA was positive at $9 million, an increase of $11 million.
Consolidated revenue increased 12% to $156 million.
Clinical Services revenue increased 20% to $130 million.
Advanced Diagnostics revenue decreased 17% to $25 million.
Net loss decreased 37% to $14 million.
Forward Guidance
The Company also issued 2024 guidance. FY 2024 Guidance Consolidated revenue is expected to be between $650 million and $660 million. Net loss is expected to be between $(72) million and $(66) million. Adjusted EBITDA is expected to be between $21 million and $24 million.
Positive Outlook
- Consolidated revenue is expected to be between $650 million and $660 million
- Adjusted EBITDA is expected to be between $21 million and $24 million
Challenges Ahead
- Net loss is expected to be between $(72) million and $(66) million
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...